CD274 and melanoma: On the other hand, in a phase I/II nivolumab study in SCLC patients [76], a phase III nivolumab study in lung squamous cell carcinoma patients [29], and a phase III study of nivolumab plus ipilimumab combination therapy in melanoma patients [60], no significant correlations were observed between PD-L1 expression and therapeutic efficacy.